Smithbridge Asset Management Inc. DE Boosts Stock Holdings in Abbott Laboratories $ABT

Smithbridge Asset Management Inc. DE boosted its stake in Abbott Laboratories (NYSE:ABT) by 117.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 88,090 shares of the healthcare product maker’s stock after purchasing an additional 47,529 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in Abbott Laboratories were worth $11,037,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ABT. All Terrain Financial Advisors LLC increased its holdings in shares of Abbott Laboratories by 14.2% in the fourth quarter. All Terrain Financial Advisors LLC now owns 2,061 shares of the healthcare product maker’s stock worth $258,000 after purchasing an additional 257 shares during the last quarter. M Holdings Securities Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at approximately $1,623,000. Signet Private Wealth LLC purchased a new position in Abbott Laboratories during the 4th quarter valued at approximately $520,000. Wellspring Financial Advisors LLC increased its stake in Abbott Laboratories by 21.3% in the 4th quarter. Wellspring Financial Advisors LLC now owns 4,070 shares of the healthcare product maker’s stock worth $510,000 after acquiring an additional 716 shares during the last quarter. Finally, Zions Bancorporation National Association UT raised its holdings in shares of Abbott Laboratories by 49.0% during the 4th quarter. Zions Bancorporation National Association UT now owns 8,790 shares of the healthcare product maker’s stock worth $1,101,000 after acquiring an additional 2,891 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ? increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by insiders.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott continues to gain attention for its cancer diagnostics growth story, with the Exact Sciences acquisition expanding its diagnostics portfolio and supportive screening data improving the long-term outlook. Mounting Evidence Backs Abbott’s Cancer Diagnostics Growth Story
• Positive Sentiment: Abbott also received a boost from news that it secured CE Mark for its Libre Duo dual glucose-ketone sensing technology, a potential growth driver in diabetes care. Abbott (ABT) Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for Diabetes
• Neutral Sentiment: ABT is being highlighted as a trending stock across financial media, suggesting rising investor interest but not necessarily a clear catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analyst commentary also noted Abbott as a blue-chip, defensive name for long-term portfolios, reinforcing its stability and dividend appeal rather than signaling a near-term earnings surprise. New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
• Negative Sentiment: Despite the positive business updates, the stock has still been trading lower, reflecting broader selling pressure and investor caution after recent gains. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Analyst Ratings Changes

A number of research firms recently weighed in on ABT. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, April 24th. Wells Fargo & Company lowered their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. The Goldman Sachs Group reduced their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Finally, Evercore lowered their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $119.09.

Abbott Laboratories Trading Down 2.3%

ABT stock opened at $89.15 on Thursday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The stock has a market capitalization of $155.29 billion, a price-to-earnings ratio of 24.97, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm’s fifty day simple moving average is $92.01 and its two-hundred day simple moving average is $108.39.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.